ClinicalTrials.gg
RecruitingNCT05245058Updated May 5, 2026

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

An Early Phase 1 interventional study of SPH5030 tablets in HER2-positive Advanced Solid Tumors, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 9 months later.
Phase
Early Phase 1
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

02

Conditions studied

  • HER2-positive Advanced Solid Tumors
03

In context

Lead sponsor

Shanghai Pharmaceuticals Holding Co., Ltd is the lead sponsor of 35 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. performance status of 0 to 1.
  2. of more than 3 months.
  3. At least one exists.( 1.1)
  4. Histologically or cytologic confirmed positive solid tumor which failed prior standard treatment or have no standard treatment.
  5. Required laboratory values including following parameters:

    ANC: ≥ 1.5 x 109/L Plt count: ≥ 90x 109/L : ≥ 90 g/L : ≤ 1.5 x , and AST: ≤ 2.5 x ULN and creatine clearance rate: ULN or≥ 50 mL/min

  6. Toxicity from previous antitumor therapy returned to baseline (except for residual hair loss effects) or ≤ class 1.
  7. Blood pregnancy test was negative within 3 days prior to first dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received the prescribed treatment at the prescribed time prior to first dosing.
  2. Known active infection within 2 weeks prior to baseline.
  3. Subjects with third space fluid that can not be controled.
  4. Subjects with uncontrolled or severe cardiovascular disease.
  5. Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
  6. Subjects with severe lung disease.
  7. Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption.
  8. Using a potent or CYP2C8 inhibitor or inducer.
  9. treatment for more than 50 days before, or in need of long-term use of steroids.
  10. Uncured other tumors within 5 years.
  11. Subjects with symptomatic , pia meningeal , or spinal cord compression due to metastasis.
  12. Evidence of chronic active or C
  13. Uncontrolled systemic diseases, including hypertension that cannot be effectively controlled after treatment.
  14. Receive any live or attenuated within 28 days prior to baseline.
  15. Evidence of severe allergies.
  16. Evidence of alcohol or drug abuse.
  17. Evidence of neurological or psychiatric disorders.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    SPH5030 tablets

    Subjects will take SPH5030 tablets orally on an empty stomach once or twice a day. Each subject will receive only one corresponding dose, and there were five dose groups: 50mg/ d, 100mg/ d, 200mg/ d, 300mg/ d and 400mg/ d.

    Drug: SPH5030 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Measurement of DLT of SPH5030 in all subjects

    Time frame: Up to 24 days

  2. Maximum tolerated dose(MTD)

    Measurement of MTD of SPH5030 in all subjects

    Time frame: Up to 24 days

  3. Number of patients with adverse events

    Adverse event type, incidence, duration, correlation with study drug

    Time frame: Up to 2 years

Secondary outcomes

  1. Maximum serum concentration (Cmax) of SPH 5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  2. Time of maximum serum concentration (Tmax) SPH 5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  3. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-14) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  4. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-Last) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  5. Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-infinity) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  6. Accumulation ratio of maximum serum concentration (Rac_Cmax) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  7. Accumulation ratio of area under the serum concentration-time curve (Rac_AUC) of the Dosing Interval (0-14D) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  8. Terminal rate constant(λz) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  9. Half-life (t1/2) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  10. Total clearance(CL) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  11. Volume of distribution(Vz) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  12. Percentage of area under the serum concentration-time curve (AUC) obtained by extrapolation (%AUCex) of SPH5030

    To characterize the PK (Pharmacokinetics) of SPH 5030

    Time frame: Up to 2 years

  13. Objective Response Rate (Investigator)

    Determination of the Objective Response Rate of all patients by investigators

    Time frame: Up to 2 years

  14. Duration of remission (DOR)

    Time from first documentation of objective response (CR or PR) to first documentation of PD/death due to any cause in absence of documented PD, based on central radiology review as per RECIST v1.1.

    Time frame: Up to 2 years

  15. Disease control rate (DCR)

    The proportion of patients with best confirmed RECIST response of CR, PR, or duration of SD.

    Time frame: Up to 2 years

  16. Progression-free survival (PFS)

    The interval between the dates of the first dose of trial treatment until first documentation of disease progression or death, whichever occurs first.

    Time frame: Up to 2 years

  17. 6-month Progression-free Survival (6mPFS)

    Number of Patients Achieving 6-month Progression-free Survival

    Time frame: Up to 2 years

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 17, 2022
StartActual
Jan 21, 2022
Primary completionEst.
Dec 21, 2026
CompletionEst.
Dec 21, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245058
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Jan 21, 2022
Primary completion
Dec 21, 2026 (estimated)
Completion
Dec 21, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Xingchen Wang
Contact
wangxc@sphchina.com
+8615811589825
Binghe Xu
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPH-5030

Start the discussion